Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04071730
Other study ID # 2019-0183
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 3, 2019
Est. completion date March 11, 2021

Study information

Verified date May 2022
Source University of Mississippi Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of oral Immulina dietary supplementation on specific immune biomarkers in the blood.


Description:

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of four weeks of daily Immulina dietary supplementation (800 mg/day) versus four weeks of daily placebo on natural killer (NK) cell numbers and/or natural killer (NK) cell activity in human peripheral blood mononuclear cells collected from human research participants who meet the trial's inclusion/exclusion criteria.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 11, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Normal, generally healthy adults between ages 18-64 and who may or may not have a controlled disease(s). Examples of controlled diseases are controlled Type-2 diabetes mellitus, controlled hypertension, controlled allergic rhinitis, etc. Exclusion Criteria: - Individuals with specific disease entities, which, in the opinion of the Principal Investigator, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barre syndrome, psoriasis, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis. - Individuals taking specific dietary supplements including probiotic, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.). If the potential participants reports usage of any of these products, they will be asked if they would be willing to withhold products for 30 days and then be re-screened for inclusion/exclusion criteria. - Individuals who are unwilling to refrain for the duration of the trial from taking the specific dietary supplements and fermented food products including probiotic, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.). - Pregnant females (because baseline immune responses, are altered by pregnancy) - Individuals unable to speak, understand and read English

Study Design


Related Conditions & MeSH terms

  • Effects of Immulina on Natural Killer Cells

Intervention

Dietary Supplement:
Immulina Dietary Supplementation
Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Locations

Country Name City State
United States University of Mississippi Medical Center Jackson Mississippi

Sponsors (1)

Lead Sponsor Collaborator
University of Mississippi Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Natural Killer (NK) cell count Differences in NK cell counts from baseline to 4 weeks 4 weeks
Secondary Natural Killer (NK) cell cytotoxic activity Differences in NK cell cytotoxic activity from baseline to 4 weeks 4 weeks
Secondary Cytokine profiles Differences in in-Vitro peripheral blood mononuclear cell (PBMC) culture supernatants' cytokine profiles from baseline to 4 weeks (IFN-a, IFN-?, IL-1ß, IL-2, IL-4, IL-6, Il-10, IL-12, Il-15 and TNFa) 4 weeks
Secondary Immune cell populations Differences in immune cell populations in PBMC from baseline to 4 weeks. 4 weeks